Alerts will be sent to your verified email
Verify Email
BPLPHARMA
|
Bharat Parenterals
|
Venus Remedies
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
0.64 % | n/a | 1.06 % |
|
Financials
|
|||
|
5 yr Average ROE
|
16.48 % | 3.75 % | 26.14 % |
|
5yr average Equity Multiplier
|
1.56 | 1.64 | 2.82 |
|
5yr Average Asset Turnover Ratio
|
1.12 | 0.78 | 1.1 |
|
5yr Avg Net Profit Margin
|
9.36 % | 2.2 % | 9.03 % |
|
Price to Book
|
4.63 | 0.87 | 8.1 |
|
P/E
|
31.24 | 14.11 | 37.6 |
|
5yr Avg Cash Conversion Cycle
|
72.73 Days | 62.86 Days | -18.02 Days |
|
Inventory Days
|
36.63 Days | 110.85 Days | 77.22 Days |
|
Days Receivable
|
106.98 Days | 37.87 Days | 81.36 Days |
|
Days Payable
|
87.71 Days | 50.32 Days | 175.58 Days |
|
5yr Average Interest Coverage Ratio
|
30.62 | 42.3 | 10.3 |
|
5yr Avg ROCE
|
23.26 % | 5.53 % | 33.27 % |
|
5yr Avg Operating Profit Margin
|
16.78 % | 12.68 % | 17.37 % |
|
5 yr average Debt to Equity
|
0.08 | 0.38 | 0.73 |
|
5yr CAGR Net Profit
|
18.21 % | n/a | 29.43 % |
|
5yr Average Return on Assets
|
10.57 % | 3.42 % | 10.17 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
73.27 % | 41.76 % | 72.51 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-1.15 % | 5.87 % | 6.76 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -6.16 % |
|
Bharat Parenterals
|
Venus Remedies
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
